Developer docs
API playgroundTry for free, no card

Search company profiles

GENEiQ

Full company profile

uuid000pheu

Namestring
GENEiQ
Websiteurl
geneiqlab.com
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Unknown
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersThe Colony, United States
HQ citystring
The Colony
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
molecular diagnostics, PCR testing services, urinary pathogen testing, respiratory pathogen testing, clinical laboratory testing
Industry3 codes
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Molecular Diagnostics
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

GENEiQ is a biotechnology company that provides a multi-faceted PCR testing portfolio targeting urinary and respiratory pathogens. The company's core offering is molecular diagnostic testing services, leveraging nucleic acid amplification to detect infectious agents in clinical samples. Specific product or service details could not be verified as the company website (geneiqlab.com) is parked with GoDaddy and contains no active content.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1PCR Testing Portfolio for Urinary Pathogens
No data
Peers10 records
TypeDirect peer
Description

Cepheid is the dominant provider of PCR-based molecular diagnostic tests for infectious diseases, including the widely used GeneXpert system with respiratory and urinary pathogen panels. It directly competes with GENEiQ in the same PCR pathogen testing categories.

TypeDirect peer
Description

BioFire produces the FilmArray syndromic PCR panels for respiratory pathogens and bloodstream infections, and is the closest comparable to GENEiQ's multi-pathogen PCR testing approach for clinical use.

TypeDirect peer
Description

Hologic's Panther Fusion system offers PCR-based respiratory and sexually transmitted infection testing, placing it as a direct competitor in the molecular diagnostics clinical testing market.

TypeDirect peer
Description

Roche, through cobas and the acquired GenMark ePlex syndromic panels, provides PCR-based respiratory and infectious disease testing that directly competes with GENEiQ's PCR pathogen portfolio.

TypeDirect peer
Description

QIAGEN develops QIAstat-Dx and NeuMoDx molecular PCR testing systems used for respiratory and other infectious disease diagnostics, making it a direct competitor in PCR pathogen testing.

TypeDirect peer
Description

Meridian develops and commercializes molecular diagnostic tests, including PCR-based assays for infectious disease pathogens, serving a comparable clinical lab and hospital customer base.

TypeBroad incumbent
Description

Quest is a large commercial clinical laboratory offering a broad menu of molecular, including PCR-based, infectious disease testing. It competes with GENEiQ for the same hospital and physician send-out volume, though across many test categories.

TypeBroad incumbent
Description

Labcorp operates a national clinical lab network with PCR-based infectious disease testing in respiratory and urinary indications. It is a broader incumbent whose offerings overlap with GENEiQ's narrower PCR pathogen focus.

TypeEmerging player
Description

T2 Biosystems develops molecular diagnostic tests for infectious disease pathogens. While its core focus has been sepsis and bloodstream infections, it operates in the same molecular clinical diagnostics space as GENEiQ.

TypeBroad incumbent
Description

BD's BD MAX System provides PCR-based molecular testing for respiratory, enteric, and sexually transmitted infections, making it an overlapping competitor in clinical infectious disease PCR testing with a broader product portfolio.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GENEiQ

Molecular Diagnosticsgeneiqlab.com

GENEiQ firmographics

Firmographics
Name
GENEiQ
Website
https://geneiqlab.com
Company type
Private
Founded year
2018
Operating status
Unknown
Headcount range
11–50 employees
Ownership category
akta.pro rank

GENEiQ industry classification

Industry
Product category
Molecular Diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAA
Molecular Diagnostics (PCR/qPCR, NGS-based assays)

Keywords

  • Molecular diagnostics
  • PCR testing services
  • Urinary pathogen testing
  • Respiratory pathogen testing
  • Clinical laboratory testing

Where GENEiQ is headquartered

Location

Headquarters

HQ city
The Colony
HQ country
United States
HQ region
North America

Markets served

GENEiQ business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

GENEiQ product offering

Product offering

Core offering

GENEiQ is a biotechnology company that provides a multi-faceted PCR testing portfolio targeting urinary and respiratory pathogens. The company's core offering is molecular diagnostic testing services, leveraging nucleic acid amplification to detect infectious agents in clinical samples. Specific product or service details could not be verified as the company website (geneiqlab.com) is parked with GoDaddy and contains no active content.

Differentiator

Problem solved

Functional benefit

Products and services

  • PCR Testing Portfolio for Urinary Pathogens

Companies that use GENEiQ

Customer profile

Ideal customer profiles1 record

GENEiQ technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

GENEiQ competitors and assessment

Company assessment

Direct peers

  • Cepheid (Danaher): Cepheid is the dominant provider of PCR-based molecular diagnostic tests for infectious diseases, including the widely used GeneXpert system with respiratory and urinary pathogen panels. It directly competes with GENEiQ in the same PCR pathogen testing categories.
  • BioFire Diagnostics (bioMérieux): BioFire produces the FilmArray syndromic PCR panels for respiratory pathogens and bloodstream infections, and is the closest comparable to GENEiQ's multi-pathogen PCR testing approach for clinical use.
  • Hologic (Panther Fusion / Diagnostics): Hologic's Panther Fusion system offers PCR-based respiratory and sexually transmitted infection testing, placing it as a direct competitor in the molecular diagnostics clinical testing market.
  • Roche Molecular Diagnostics (cobas / GenMark ePlex): Roche, through cobas and the acquired GenMark ePlex syndromic panels, provides PCR-based respiratory and infectious disease testing that directly competes with GENEiQ's PCR pathogen portfolio.
  • QIAGEN (NeuMoDx, QIAstat-Dx): QIAGEN develops QIAstat-Dx and NeuMoDx molecular PCR testing systems used for respiratory and other infectious disease diagnostics, making it a direct competitor in PCR pathogen testing.
  • Meridian Bioscience: Meridian develops and commercializes molecular diagnostic tests, including PCR-based assays for infectious disease pathogens, serving a comparable clinical lab and hospital customer base.

Broad incumbents

  • Quest Diagnostics: Quest is a large commercial clinical laboratory offering a broad menu of molecular, including PCR-based, infectious disease testing. It competes with GENEiQ for the same hospital and physician send-out volume, though across many test categories.
  • Labcorp (Laboratory Corporation of America): Labcorp operates a national clinical lab network with PCR-based infectious disease testing in respiratory and urinary indications. It is a broader incumbent whose offerings overlap with GENEiQ's narrower PCR pathogen focus.
  • Becton, Dickinson and Company (BD) — BD MAX System: BD's BD MAX System provides PCR-based molecular testing for respiratory, enteric, and sexually transmitted infections, making it an overlapping competitor in clinical infectious disease PCR testing with a broader product portfolio.

Emerging players

  • T2 Biosystems: T2 Biosystems develops molecular diagnostic tests for infectious disease pathogens. While its core focus has been sepsis and bloodstream infections, it operates in the same molecular clinical diagnostics space as GENEiQ.

Market position

Customer concentration

GENEiQ social profiles

Digital presence

GENEiQ financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GENEiQ leadership team

Management profile

Number of profiles

Profiles2 records

GENEiQ funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GENEiQ M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GENEiQ

What does GENEiQ do?

GENEiQ is a biotechnology company that provides a multi-faceted PCR testing portfolio targeting urinary and respiratory pathogens. The company's core offering is molecular diagnostic testing services, leveraging nucleic acid amplification to detect infectious agents in clinical samples. Specific product or service details could not be verified as the company website (geneiqlab.com) is parked with GoDaddy and contains no active content.

When was GENEiQ founded?

GENEiQ was founded in 2018. It employs 11 to 50 people.

Where is GENEiQ based?

GENEiQ is headquartered in The Colony, United States, in the North America region.

Who are GENEiQ's main competitors?

Direct peers on record are Cepheid (Danaher), BioFire Diagnostics (bioMérieux), Hologic (Panther Fusion / Diagnostics), Roche Molecular Diagnostics (cobas / GenMark ePlex), QIAGEN (NeuMoDx, QIAstat-Dx) and Meridian Bioscience. Broad incumbents are Quest Diagnostics, Labcorp (Laboratory Corporation of America) and Becton, Dickinson and Company (BD) — BD MAX System. T2 Biosystems is listed as an emerging player.

Does GENEiQ have an API?

No public API is recorded for GENEiQ.

What industry is GENEiQ in?

GENEiQ's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR), with a secondary code of HLAHAAAD, Molecular Diagnostics (PCR/NAAT/NGS-based IVD). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Labroots Trending Science NewsDr. Agnes Caruso: From Academia to Advancing Patient-Centered DiagnosticsDr. Agnes Caruso is featured discussing her career transition from academia to diagnostics and her work as Head Consultant at Caruso International and founder of geneIQ, focusing on improving patient diagnostics with AI and multi-omics data.American City Business JournalsGeneIQ snags health care veteran Sami Shihabi as Chief Commercial OfficerGeneIQ appointed Sami Shihabi as Chief Commercial Officer, bringing over 25 years of health care experience. He most recently led the Women’s Health Diagnostics and Gastroenterology Precision Medicine divisions at Progenity as Chief Commercial Officer.PR NewswireGeneIQ Announces Appointment of New Chief Commercial OfficerGeneIQ, a molecular diagnostics company based in Dallas, Texas, announced the appointment of Sami Shihabi as its new Chief Commercial Officer. Shihabi brings more than 25 years of healthcare industry experience, having previously held CCO roles at Progenity and Prometheus Laboratories, and will lead GeneIQ's commercial operations including sales, marketing, and revenue cycle management. The company stated that Shihabi's appointment is aimed at expanding GeneIQ's commercial presence in the precision medicine space.PR NewswireGeneIQ Leads Education and Implementation of PharmacogenomicsGeneIQ, a Dallas-based molecular diagnostics company, is leading education and implementation of Pharmacogenomics (PGx) testing to address adverse drug reactions (ADRs), which are the 4th leading cause of death in the United States, costing the healthcare system over $800 billion annually. The company provides clinicians with AI-powered diagnostic tools that analyze genetic profiles to optimize medication selection and dosages, tailoring real-time treatment plans for patients. GeneIQ's Chief Scientific Officer highlighted that over 90% of doctors recognize PGx's clinical potential, though only 10-14% feel prepared to implement it, noting the company's expansion efforts to broaden adoption of pharmacogenomic testing.PR NewswireGeneIQ Announces New Diagnostic Panel Intended to Enhance Treatment of Various Infectious DiseasesGeneIQ, a molecular diagnostics company based in Dallas, announced the launch of its One Choice® Report and Antimicrobial Stewardship Program on June 29, 2022. The new product uses PCR-based detection to identify pathogens causing urinary tract infections, women's health infections, sexually transmitted infections, and wound infections, while also incorporating antibiotic resistance markers and patient allergy profiles to guide treatment decisions. The company stated the program aims to promote appropriate antimicrobial use, improve patient outcomes, and reduce community spread of drug-resistant infections.PR NewswireGeneIQ Partners with Synchrony Pharmacy to Provide Real-Time Pharmacogenomics Services to Nursing Facilities NationwideGeneIQ, a molecular diagnostics laboratory based in Dallas, Texas, has partnered with Synchrony Pharmacy of Louisville, Kentucky, to provide real-time pharmacogenomics services to skilled nursing facilities across the United States. The partnership enables Synchrony Pharmacy to utilize GeneIQ's Live Dynamic Clinical Decision Support tools, which combine patient genetic results with medication risk factors to reduce prescribing risks and improve treatment outcomes for long-term care residents. The companies have already completed integrations allowing them to impact around 200 Skilled Nursing Facilities, with plans to expand to additional facilities nationwide while helping nursing homes improve CMS quality measures.PR NewswireGeneIQ Partners with Local Businesses and Employers to Offer On-site COVID-19 Testing and Free Vaccines; Announces Plans to Expand Testing NationwideGeneIQ, a Dallas-based molecular diagnostics company, announced the expansion of its Workplace Safety initiative to offer on-site COVID-19 testing and vaccination services to businesses in over twenty new states starting in February 2022. The company provides rapid antigen tests, PCR tests with 24-48 hour turnaround, and FDA-approved COVID-19 vaccines including Moderna, Pfizer, and Johnson & Johnson at no cost to participating organizations. GeneIQ has partnered with over 500 corporations, institutions, and school districts throughout the pandemic and aims to assist businesses nationwide in maintaining safe workplaces during the Omicron wave and future variant concerns.